

Considering the methodological limitations in the evidence base of antidepressants for depression: A reanalysis of a network meta-analysis

Klaus Munkholm ^a, Asger Sand Paludan-Müller ^a, Kim Boesen ^a

^a Nordic Cochrane Centre, Rigshospitalet, Copenhagen, Denmark

S2 Table

S2 Table. Rating scales used in the included placebo-controlled trials (n = 304).¹

| Scale | Number of trials | Number of treatment arms |
|------------------|------------------|--------------------------|
| HAMD17 | 137 | 198 |
| HAMD21 | 92 | 139 |
| HAMD24 | 13 | 22 |
| HAMD29 | 1 | 2 |
| HAMD31 | 1 | 2 |
| HAMD unspecified | 22 | 25 |
| IDS-IVR-30 | 1 | 1 |
| MADRS | 29 | 50 |
| NA | 8 | 12 |

NA: not available; HAMD17: 17-item Hamilton depression rating scale; IDS-IVR-30: 30-item Inventory of Depressive Symptomatology-Self Report; MADRS: Montgomery-Åsberg Depression Rating Scale.

References

1. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. *Lancet* 2018 doi: 10.1016/S0140-6736(17)32802-7 [published Online First: 2018/02/27]